Trial Profile
A Phase II Window of Opportunity Trial With GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Trametinib (Primary)
- Indications Oropharyngeal cancer
- Focus Therapeutic Use
- 20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research
- 03 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 06 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.